Titillating story diverts focus of antisense trial

The hubbub surrounding publication of a narrowly focused and incorrect Wall Street Journalarticle has threatened to obscure the larger issues in the antisense trial between Calgene Inc. and Enzo Biochem Inc., some of which have potential implications for all biotech companies.

The CGNE-ENZ trial has ended, and a decision from the judge in the U.S. District Court in Delaware is expected in September or October...